BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 27246973)

  • 1. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.
    Keppler S; Weiβbach S; Langer C; Knop S; Pischimarov J; Kull M; Stühmer T; Steinbrunn T; Bargou R; Einsele H; Rosenwald A; Leich E
    Oncotarget; 2016 Jun; 7(25):38762-38774. PubMed ID: 27246973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
    Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
    Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.
    Serizawa M; Kusuhara M; Ohnami S; Nagashima T; Shimoda Y; Ohshima K; Mochizuki T; Urakami K; Yamaguchi K
    Anticancer Res; 2016 Jun; 36(6):2733-44. PubMed ID: 27272783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
    Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
    Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RTK mutations and human syndromeswhen good receptors turn bad.
    Robertson SC; Tynan JA; Donoghue DJ
    Trends Genet; 2000 Jun; 16(6):265-71. PubMed ID: 10827454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.
    Duplaquet L; Figeac M; Leprêtre F; Frandemiche C; Villenet C; Sebda S; Sarafan-Vasseur N; Bénozène M; Vinchent A; Goormachtigh G; Wicquart L; Rousseau N; Beaussire L; Truant S; Michel P; Sabourin JC; Galateau-Sallé F; Copin MC; Zalcman G; De Launoit Y; Fafeur V; Tulasne D
    Mol Cancer Ther; 2019 Jun; 18(6):1137-1148. PubMed ID: 30926633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.
    Tao Z; Liu J; Li T; Xu H; Chen K; Zhang J; Zhou H; Sun J; Han J; Guo Z; Yang H; Cao WM; Hu X
    Front Oncol; 2021; 11():741142. PubMed ID: 34650924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW; Klempner SJ; Ou SI
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
    Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
    J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.
    Wagner JP; Wolf-Yadlin A; Sevecka M; Grenier JK; Root DE; Lauffenburger DA; MacBeath G
    Sci Signal; 2013 Jul; 6(284):ra58. PubMed ID: 23861540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
    Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.
    Rand V; Huang J; Stockwell T; Ferriera S; Buzko O; Levy S; Busam D; Li K; Edwards JB; Eberhart C; Murphy KM; Tsiamouri A; Beeson K; Simpson AJ; Venter JC; Riggins GJ; Strausberg RL
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14344-9. PubMed ID: 16186508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
    Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
    Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
    Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
    Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.
    de Larrea CF; Navarro A; Tejero R; Tovar N; Díaz T; Cibeira MT; Rosiñol L; Ferrer G; Rovira M; Rozman M; Monzó M; Bladé J
    Clin Cancer Res; 2012 Jul; 18(13):3697-704. PubMed ID: 22539802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.